A new Aclasta study emphasizes the importance of treating patients for osteoporosis after a hip fracture

November 2007

A new Aclasta study emphasizes the importance of treating patients for osteoporosis after a hip fracture.

Elderly patients who break a hip have a high risk of disability, future fractures, and even death.

Now there's evidence that Aclasta (zoledronic acid) reduces the risk of a second fracture and improves survival in these patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Myths prevent many people from getting flu vaccine
Respiratory & Allergy Canadian Thoracic Society guidelines will improve COPD treatment
Celsentri (maraviroc) is a new HIV drug in Canada
new HIV drug, Isentress (raltegravir)
Infectious Diseases Methicillin-resistant Staph aureus (MRSA) infections are rising
Diabetes Exubera (inhaled insulin) will NOT be launched in Canada
Psychiatry potentially fatal arrhythmias with haloperidol
Smoking Cessation bizarre psychiatric effects in patients using Champix (varenicline) to stop smoking
Gastroenterology which antibiotic regimens to use for treating H. pylori
Supplements some mothers and babies aren't getting enough vitamin D
Supplements Akavar 20/50 for weight loss
Osteoporosis new dosing for Actonel (risedronate)
Osteoporosis A new Aclasta study emphasizes the importance of treating patients for osteoporosis after a hip fracture
Pediatrics The recent withdrawal of infant cough and cold OTCs has parents asking how to alleviate cold symptoms in young children
Pediatrics what to do if a child's liquid antibiotic is accidentally left out of the refrigerator